Canvas Wealth Advisors LLC Sells 26,302 Shares of QIAGEN N.V. $QGEN

Canvas Wealth Advisors LLC lowered its position in shares of QIAGEN N.V. (NYSE:QGEN) by 80.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,336 shares of the company’s stock after selling 26,302 shares during the period. Canvas Wealth Advisors LLC’s holdings in QIAGEN were worth $323,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. SVB Wealth LLC purchased a new stake in shares of QIAGEN during the first quarter worth about $31,000. Farther Finance Advisors LLC raised its position in QIAGEN by 400.5% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock valued at $51,000 after purchasing an additional 849 shares during the last quarter. Hilltop National Bank bought a new position in QIAGEN during the 2nd quarter valued at approximately $66,000. ANTIPODES PARTNERS Ltd purchased a new stake in QIAGEN in the 1st quarter worth approximately $94,000. Finally, GAMMA Investing LLC grew its position in shares of QIAGEN by 93.9% in the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock worth $118,000 after buying an additional 1,425 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

QIAGEN Stock Performance

Shares of QGEN stock opened at $48.29 on Monday. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. The company’s fifty day moving average price is $47.00 and its 200-day moving average price is $45.85. The stock has a market cap of $10.73 billion, a PE ratio of 28.53, a price-to-earnings-growth ratio of 2.54 and a beta of 0.66. QIAGEN N.V. has a 12 month low of $37.63 and a 12 month high of $51.88.

QIAGEN (NYSE:QGEN) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.60. The company had revenue of $533.54 million during the quarter, compared to analysts’ expectations of $523.97 million. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. QIAGEN’s revenue was up 7.7% on a year-over-year basis. During the same period last year, the company posted $0.55 EPS. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, equities analysts expect that QIAGEN N.V. will post 2.26 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on QGEN. Barclays set a $53.00 target price on QIAGEN and gave the company an “overweight” rating in a report on Thursday, October 2nd. Weiss Ratings reissued a “hold (c+)” rating on shares of QIAGEN in a research report on Wednesday, October 8th. Wall Street Zen cut shares of QIAGEN from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. UBS Group lifted their target price on shares of QIAGEN from $48.00 to $50.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Finally, Cowen reissued a “hold” rating on shares of QIAGEN in a research note on Thursday, August 7th. Three analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, QIAGEN presently has an average rating of “Hold” and a consensus target price of $49.69.

QIAGEN Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.